The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A comparison of paroxetine and placebo in depressed outpatients
Abstract
To compare the safety and efficacy of paroxetine (n= 167) and placebo (n= 169), data from 4 centres using the same protocol were pooled. A double‐blind parallel group design was used, with therapy lasting 6 weeks. Significant differences between paroxetine‐ and placebo‐treated patients were found on the major efficacy outcome variables by week 2 and on all efficacy variables by week 4 of the study. Improvement on the sleep factor of the Hamilton Rating Scale for Depression was found after 7 d. Observer and patient global efficacy ratings were in agreement by week 4. No serious adverse events occurred, and paroxetine had no clinically significant effects on vital signs or laboratory safety data. Side effects were more common on paroxetine and were similar to other serotonin reuptake inhibitors. In general, these were well tolerated and did not lead to dropout. Symptoms of increased arousal were not seen during early therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Dunbar et al., 1993) found that HAMD sleep scores were significantly more improved with paroxetine (10-50mg) than placebo.”
From Antidepressants and their effect on sleep (2005) · cites this paper as Dunbar et al., 1993
Citations
Cites
Mas, M., Zahradnik, M. A., Martino, V., & Davidson, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)91360-5 · Cited by 86 · cited 1×
“This type of symptom has been seen with other 5-HT uptake inhibitors, and is likely to be a class phenomenon (13-16).”
Background
Flagged first, then by citations
Research works printed but not linked: 16
- 10.1007/BF00179933 · DOI
- 10.1177/026988118700100405 · DOI
- 10.1111/j.1600-0447.1989.tb07171.x · DOI
- 10.1111/j.1600-0447.1989.tb07161.x · DOI
- 10.1007/BF00428539 · DOI
- 10.1111/j.1600-0447.1989.tb07173.x · DOI
- 10.1111/j.1600-0447.1989.tb07174.x · DOI
- 10.1111/j.1600-0447.1989.tb07176.x · DOI
- 10.1111/j.1600-0447.1989.tb07163.x · DOI
- 10.1111/j.1600-0447.1989.tb07188.x · DOI
- Costart – Coding Symbols for Thesaurus of Adverse Reaction Terms, 1989, Department of Health and Human Services, F.D.A. Centre for Drug Evaluation Research, Office of Epidemiology and Biostatistics
- 10.1111/j.1600-0447.1989.tb07187.x · DOI
- 10.1111/j.1476-5381.1986.tb14580.x · DOI
- Doogan DP., 1989, Sertraline, a new antidepressant, J Clin Psychiatry, 49, 46
- Herman JB., 1990, Fluotexine induced sexual dysfunction, J Clin Psychiatry, 51, 25
- 10.1007/BF00166984 · DOI
Cited by
Sorted by citations
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Morrow, G. R., Hickok, J. T., Roscoe, J. A., Raubertas, R. F., Andrews, P. L. R., Flynn, P. J., Hynes, H. E., Banerjee, T. K., Kirshner, J. J., & King, D. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.070 · Cited by 324
Antidepressants and their effect on sleep
Mayers, A. G., & Baldwin, D. S. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.726 · Cited by 323
Metadata
- Authors
- Dunbar, G. C., Claghorn, J. L., Kiev, A., Rickels, K., & Smith, W. T.
- Affiliations
- New York University (US)
- Corresponding author
- Dunbar, G. C.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 1993-05
- Volume
- 87
- Issue
- 5
- Pages
- 302-305
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W2118783348
- Cited by
- 42
- References
- 1
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2019: 1 · 2015: 1 · 2013: 1 · 2012: 2
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Psychiatrica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- paroxetine, depression, outpatients, placebo comparison, serotonin reuptake inhibitors, antidepressant efficacy, adverse effects, tolerability, Hamilton Depression Rating Scale, sleep
- MeSH terms
- Adolescent, Adult, Aged, Ambulatory Care, Arousal, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Severity of Illness Index, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
